According to our current protocol using QFT-GIT with supplementary TST results, the prevalence of LTBI patients with rheumatic diseases before starting TNF-α antagonist therapy was 29.5% (46/156) at the initial screening. The gene discussed is TNF; the disease is rheumatic disorder.